Cite
Omori S, Harada H, Mori K, et al. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2021;40(1):106-114doi: 10.1007/s10637-021-01155-w.
Omori, S., Harada, H., Mori, K., Hisamatsu, Y., Tsuboguchi, Y., Yoshioka, H., Morinaga, R., Daga, H., Kurata, T., & Takahashi, T. (2022). Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Investigational new drugs, 40(1), 106-114. https://doi.org/10.1007/s10637-021-01155-w
Omori, Shota, et al. "Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer." Investigational new drugs vol. 40,1 (2022): 106-114. doi: https://doi.org/10.1007/s10637-021-01155-w
Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 08. PMID: 34495421.
Copy
Download .nbib